Attached files
| file | filename |
|---|---|
| S-1 - S-1 - Prelude Therapeutics Inc | d85697ds1.htm |
| EX-10.8 - EX-10.8 - Prelude Therapeutics Inc | d85697dex108.htm |
| EX-10.7 - EX-10.7 - Prelude Therapeutics Inc | d85697dex107.htm |
| EX-10.6 - EX-10.6 - Prelude Therapeutics Inc | d85697dex106.htm |
| EX-5.1 - EX-5.1 - Prelude Therapeutics Inc | d85697dex51.htm |
| EX-4.3 - EX-4.3 - Prelude Therapeutics Inc | d85697dex43.htm |
| EX-1.1 - EX-1.1 - Prelude Therapeutics Inc | d85697dex11.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated July 23, 2020 (except for the reverse stock split described in Note 11, as to which the date is September 21, 2020), in the Registration Statement (Form S-1) and related Prospectus of Prelude Therapeutics Incorporated dated January 4, 2021.
/s/ Ernst & Young LLP
Philadelphia, Pennsylvania
January 4, 2021